Ministry of Health, Labour and Welfare, Japan

• NCT01214343

  Phase 3, Status unknown, 190 people, 5 Oct 2010

• NCT00544128

  Collaborator, Phase 4, Completed, 109 people, 16 Oct 2007

• NCT00355667

  Collaborator, Phase 4, Completed, 320 people, 24 Jul 2006

• NCT00295789

  Collaborator, Phase 3, Completed, 253 people, 24 Feb 2006

• NCT00225849

  Phase 4, Status unknown, 10,000 people, 26 Sept 2005

• NCT00221104

  Collaborator, Phase 3, Completed, 1,578 people, 22 Sept 2005

• NCT00211705

  Collaborator, Phase 4, Completed, 8,000 people, 21 Sept 2005

• NCT00198562

  Phase 4, Status unknown, 2,600 people, 20 Sept 2005

• NCT00190554

  Collaborator, Phase 3, Terminated, 330 people, 19 Sept 2005

• NCT00147147

  Collaborator, Phase 3, Completed, 280 people, 7 Sept 2005

• NCT00128037

  Collaborator, Phase 2, Completed, 75 people, 9 Aug 2005

• NCT00112086

  Collaborator, Phase 2, Completed, 56 people, 30 May 2005

• Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z-Drugs: A Target Trial Emulation

  23AA2003, 8 Oct 2026

• Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study

  H30-Seisaku-Shitei-008, 11 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Mathematical Derivation of the Human Lifespan Limit

  Figshare, 20 Feb 2026